Technical Analysis for VNDA - Vanda Pharmaceuticals Inc.

Grade Last Price % Change Price Change
F 3.75 -1.57% -0.06
VNDA closed down 1.57 percent on Monday, March 18, 2024, on 71 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
Oversold Stochastic Weakness 0.00%
Oversold Stochastic Weakness -1.57%
NR7 Range Contraction -1.32%
Narrow Range Bar Range Contraction -1.32%
Down 3 Days in a Row Weakness -1.32%
Oversold Stochastic Weakness -1.32%
Oversold Stochastic Weakness -2.34%
Oversold Stochastic Weakness -3.35%
50 DMA Resistance Bearish -6.37%
MACD Bearish Centerline Cross Bearish -6.37%

   Recent Intraday Alerts

Alert Time
1.5x Volume Pace about 17 hours ago
Down 2 % about 17 hours ago
Fell Below Previous Day's Low about 17 hours ago
Down 1% about 17 hours ago
2x Volume Pace 3 days ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Vanda Pharmaceuticals Inc. Description

Vanda Pharmaceuticals, Inc., a biopharmaceutical company, offers development and commercialization of products for the treatment of central nervous system disorders. The company provides Fanapt, a compound for the treatment of schizophrenia; and VLY-686, a small molecule neurokinin-1 receptor (NK-1R) antagonist that has indications for chemotherapy-induced nausea and vomiting, post-operative nausea and vomiting, alcohol dependence, anxiety, depression, and pruritus. Its product in clinical development includes Tasimelteon, which completed Phase III clinical trials for the treatment of circadian rhythm sleep disorders, as well as completed Phase IIb/III trials for the treatment of major depressive disorder and insomnia. Vanda Pharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Washington, District of Columbia.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Clinical Development Alcohol Oncology Organic Compounds Chemical Compounds Chemotherapy Schizophrenia Central Nervous System Disorders Major Depressive Disorder Nervous System Disorders Depression Depressive Disorder Sleep Disorders Pyridines Treatment Of Major Depressive Disorder Insomnia Nausea Sedatives Treatment Of Central Nervous System Disorders Treatment Of Schizophrenia Pruritus Chemotherapy Induced Nausea Fanapt Iloperidone

Is VNDA a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 7.0
52 Week Low 3.295
Average Volume 932,199
200-Day Moving Average 4.76
50-Day Moving Average 4.00
20-Day Moving Average 4.16
10-Day Moving Average 3.88
Average True Range 0.19
RSI (14) 39.02
ADX 19.8
+DI 21.40
-DI 26.28
Chandelier Exit (Long, 3 ATRs) 4.20
Chandelier Exit (Short, 3 ATRs) 4.28
Upper Bollinger Bands 4.77
Lower Bollinger Band 3.56
Percent B (%b) 0.16
BandWidth 28.99
MACD Line -0.09
MACD Signal Line -0.02
MACD Histogram -0.0663
Fundamentals Value
Market Cap 215.77 Million
Num Shares 57.5 Million
EPS 0.04
Price-to-Earnings (P/E) Ratio 93.75
Price-to-Sales 1.24
Price-to-Book 0.44
PEG Ratio -2.42
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.92
Resistance 3 (R3) 3.93 3.88 3.89
Resistance 2 (R2) 3.88 3.84 3.88 3.88
Resistance 1 (R1) 3.82 3.81 3.79 3.81 3.87
Pivot Point 3.77 3.77 3.76 3.77 3.77
Support 1 (S1) 3.70 3.73 3.68 3.69 3.63
Support 2 (S2) 3.66 3.70 3.65 3.62
Support 3 (S3) 3.59 3.66 3.61
Support 4 (S4) 3.58